The last time I spoke about Praxis Precision Medicines, Inc. (PRAX), it was in a Seeking Alpha article entitled "Praxis: Still A 'Hold' Despite Interim Analysis Setback Of Ulixacaltamide." At that ...
BOSTON - Praxis Precision Medicines Inc. (NASDAQ: PRAX) announced that the Independent Data Monitoring Committee (IDMC) has recommended halting Study 1 of the Essential3 program, which is evaluating ...
PRAX-628 Phase 2 study for treatment of focal epilepsy expected to initiate in 4Q23 BOSTON, May 11, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines (PRAX), Inc. (NASDAQ: PRAX), a clinical-stage ...
Hosted on MSN
Praxis Precision Medicines’ PRAX-628 Study: A Potential Game-Changer for Focal Seizures
Praxis Precision Medicines, Inc. ((PRAX)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert ...
Earnings call Praxis reported standout topline results from the RADIANT study of vimatrogene in focal epilepsy, with a 56% median seizure reduction and 60% responder rate. Management reaffirmed POWER1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results